CDKN2A and esophageal squamous cell carcinoma: Given that the p53 and Cdk4/6-cyclin D1-p16-Rb genes are commonly mutated in ESCC, it was hypothesized that ART is potentially clinically useful as a chemotherapeutic or adjuvant drug for ESCC.